Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/28/2019 | 07:20am EDT

DGAP Total Voting Rights Announcement: Evotec SE / Total Voting Rights Announcement
Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

28.06.2019 / 13:12
Total Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Publication of total number of voting rights

1. Details of issuer
Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany

2. Type of capital measure
  Type of capital measure Date of status / date of effect
X Conditional capital increase (Sec. 41 para. 2 WpHG) 28.06.2019
  Other capital measure (Sec. 41 para. 1 WpHG)

3. New total number of voting rights:
149896057



28.06.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Internet: www.evotec.com

 
End of News DGAP News Service

832899  28.06.2019 

fncls.ssp?fn=show_t_gif&application_id=832899&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC SE
08/19EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
08/15EVOTEC : reports first half-year 2019 results and corporate updates
AQ
08/14EVOTEC : Reports first half-year 2019 results and corporate updates
EQ
08/08EVOTEC : to report first-half year 2019 results on 14 August 2019
AQ
08/08Bayer buys BlueRock in $600 million bet on stem cell therapies
RE
08/07EVOTEC : To report first half-year 2019 results on 14 august 2019
EQ
08/01EVOTEC SE : New IMI project 'GNA Now' kicks off its battle against antimicrobial..
EQ
07/31EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
07/26EVOTEC : P2X3 antagonist demonstrates efficacy against refractory chronic cough ..
AQ
07/25EVOTEC SE : P2x3 antagonist demonstrates efficacy against refractory chronic cou..
EQ
More news
Financials (EUR)
Sales 2019 420 M
EBIT 2019 59,7 M
Net income 2019 41,2 M
Finance 2019 36,2 M
Yield 2019 -
P/E ratio 2019 69,8x
P/E ratio 2020 46,7x
EV / Sales2019 6,69x
EV / Sales2020 5,63x
Capitalization 2 850 M
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 27,60  €
Last Close Price 19,21  €
Spread / Highest target 71,8%
Spread / Average Target 43,7%
Spread / Lowest Target 19,8%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE9.50%3 161
IQVIA HOLDINGS INC34.91%30 701
LONZA GROUP36.75%26 363
INCYTE CORPORATION32.91%18 177
CELLTRION, INC.--.--%16 143
EXACT SCIENCES CORPORATION89.89%15 300